Durvalumab plus etoposide-carboplatin for advanced digestive neuroendocrine carcinoma: a phase III trial (JCOG2107E).
CLINICAL TRIAL REGISTRATION jRCT2031230456 (https://jrct.mhlw.go.jp/latest-detail/jRCT2031230456).
We have 2 of 19 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
CLINICAL TRIAL REGISTRATION jRCT2031230456 (https://jrct.mhlw.go.jp/latest-detail/jRCT2031230456).
Reduced starting dose and RDI <80% were not associated with inferior survival, suggesting that individualized dose modification may be feasible, and future prospective studies are warranted to refine NFF dosing strategies.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.